{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T09:56:30Z","timestamp":1781949390433,"version":"3.54.5"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012990","name":"Universit\u00e0 degli Studi di Siena","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012990","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Interstitial lung diseases (ILD) are a heterogeneous group of illnesses of known and unknown aetiology. Differential diagnosis among the three disorders is often challenging. Specific biomarkers with good sensitivity and specificity are therefore needed to predict clinical outcome and guide clinical decisions. The aim of this study was to investigate inflammatory\/fibrotic biomarkers, to determine whether single mediators or panels of mediators could be useful to stratify patients into three distinct domains: sarcoidosis, idiopathic pulmonary fibrosis (IPF) and chronic hypersensitivity pneumonitis (cHP). A total of 163 ILD patients monitored at Siena Referral Centre for Sarcoidosis and other Interstitial Lung Diseases were enrolled in the study. Clinical data, pulmonary function tests and biochemical analytes were retrospectively collected. SAA levels were detected by ELISA kit and Krebs von den Lungen 6 (KL-6) were measured by CLEIA method, for sarcoidosis, cHP and IPF patients. Multiple comparison analysis showed significant differences in C reactive protein (CRP), white blood cell count (WBC) and creatinine levels between the three groups. In the logistic regression model, KL-6, CRP and WBC showed areas under curves (AUC) 0.86, for sarcoidosis diagnosis. The logistic regression model KL-6 and SAA showed the best performance with an AUC 0.81 for discriminating IPF than cHP and sarcoidosis. For differential diagnosis of IPF and cHP, KL-6 and SAA were considered in the logistic regression model, showed an AUC 0.79. The combination of serum biomarkers proposed here offers insights into the pathobiology of ILDs. These panels of bioindicators will improve diagnostic accuracy and will be useful in the clinical management of ILDs.<\/jats:p>","DOI":"10.1007\/s12026-020-09158-0","type":"journal-article","created":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T03:43:52Z","timestamp":1603338232000},"page":"414-421","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Utility of serological biomarker\u2019 panels for diagnostic accuracy of interstitial lung diseases"],"prefix":"10.1007","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1118-3223","authenticated-orcid":false,"given":"Laura","family":"Bergantini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriana","family":"d\u2019Alessandro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Vietri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Domenico","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Cameli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Acerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piersante","family":"Sestini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bargagli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,22]]},"reference":[{"key":"9158_CR1","doi-asserted-by":"publisher","unstructured":"Bargagli E, Cameli P, Carleo A, Refini RM, Bergantini L, D'alessandro M, Vietri L, Perillo F, Volterrani L, Rottoli P, Bini L, Landi C. The effect of cigarette smoking on bronchoalveolar lavage protein profiles from patients with different interstitial lung diseases. Panminerva Med. 2020;62(2):109\u2013115. https:\/\/doi.org\/10.23736\/S0031-0808.19.03754-6.","DOI":"10.23736\/S0031-0808.19.03754-6"},{"issue":"1","key":"9158_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10753-019-01059-1","volume":"43","author":"P Cameli","year":"2020","unstructured":"Cameli P, Carleo A, Bergantini L, Landi C, Prasse A, Bargagli E. Oxidant\/antioxidant disequilibrium in idiopathic pulmonary fibrosis pathogenesis. Inflammation. 2020;43(1):1\u20137.","journal-title":"Inflammation."},{"issue":"5","key":"9158_CR3","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1097\/MCP.0b013e328363f48d","volume":"19","author":"CJ Ryerson","year":"2013","unstructured":"Ryerson CJ, Collard HR. Update on the diagnosis and classification of ILD. Curr Opin Pulm Med. 2013;19(5):453\u20139.","journal-title":"Curr Opin Pulm Med"},{"key":"9158_CR4","doi-asserted-by":"publisher","first-page":"8565423","DOI":"10.1155\/2019\/8565423","volume":"2019","author":"L Bergantini","year":"2019","unstructured":"Bergantini L, Bianchi F, Cameli P, Mazzei MA, Fui A, Sestini P, et al. Prognostic biomarkers of Sarcoidosis: a comparative study of serum Chitotriosidase, ACE, lysozyme, and KL-6. Dis Markers. 2019;2019:8565423.","journal-title":"Dis Markers"},{"issue":"3","key":"9158_CR5","first-page":"207","volume":"99","author":"P Cameli","year":"2020","unstructured":"Cameli P, Gonnelli S, Bargagli E, d\u2019Alessandro M, Bergantini L, Favetta V, et al. The role of urinary calcium and Chitotriosidase in a cohort of chronic Sarcoidosis patients. Respir Int Rev Thorac Dis. 2020;99(3):207\u201312.","journal-title":"Respir Int Rev Thorac Dis"},{"key":"9158_CR6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.cca.2019.10.010","volume":"500","author":"A Enyedi","year":"2020","unstructured":"Enyedi A, Csongr\u00e1di A, Altorjay IT, Beke GL, V\u00e1radi C, Enyedi EE, et al. Combined application of angiotensin converting enzyme and chitotriosidase analysis improves the laboratory diagnosis of sarcoidosis. Clin Chim Acta. 2020;500:155\u201362.","journal-title":"Clin Chim Acta"},{"issue":"5","key":"9158_CR7","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/MCP.0000000000000301","volume":"22","author":"CA Bonham","year":"2016","unstructured":"Bonham CA, Strek ME, Patterson KC. From granuloma to fibrosis: sarcoidosis associated pulmonary fibrosis. Curr Opin Pulm Med. 2016;22(5):484\u201391.","journal-title":"Curr Opin Pulm Med"},{"key":"9158_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ejim.2020.04.006","volume":"78","author":"M d\u2019Alessandro","year":"2020","unstructured":"d\u2019Alessandro M, Bergantini L, Perrone A, Cameli P, Cameli M, Prasse A, et al. Serial investigation of angiotensin-converting enzyme in sarcoidosis patients treated with angiotensin-converting enzyme inhibitor. Eur J Intern Med. 2020;78:58\u201362.","journal-title":"Eur J Intern Med"},{"key":"9158_CR9","doi-asserted-by":"publisher","unstructured":"Lanzarone N, Gentili F, Alonzi V, Bergantini L, d'Alessandro M, Rottoli P, Refini RM, Pieroni M, Vietri L, Bianchi F, Mazzei MA, Volterrani L, Perrone A, Cameli P, Bargagli E, Sestini P. Bronchoalveolar lavage and serum KL-6 concentrations in chronic hypersensitivity pneumonitis: correlations with radiological and immunological features. Intern Emerg Med. 2020;15(7):1247\u20131254. https:\/\/doi.org\/10.1007\/s11739-020-02281-8.","DOI":"10.1007\/s11739-020-02281-8"},{"issue":"2","key":"9158_CR10","doi-asserted-by":"publisher","first-page":"026008","DOI":"10.1088\/1752-7163\/ab0233","volume":"27;13","author":"P Cameli","year":"2019","unstructured":"Cameli P, Bargagli E, Bergantini L, Refini RM, Pieroni M, Sestini P, et al. Evaluation of multiple-flows exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease. J Breath Res. 2019;27;13(2):026008.","journal-title":"J Breath Res"},{"issue":"1","key":"9158_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11739-018-1960-5","volume":"14","author":"E Bargagli","year":"2019","unstructured":"Bargagli E, Di Masi M, Perruzza M, Vietri L, Bergantini L, Torricelli E, et al. The pathogenetic mechanisms of cough in idiopathic pulmonary fibrosis. Intern Emerg Med. 2019;14(1):39\u201343.","journal-title":"Intern Emerg Med"},{"key":"9158_CR12","doi-asserted-by":"publisher","unstructured":"Bergantini L, d'Alessandro M, Cameli P, Carleo A, Landi C, Vietri L, Lanzarone N, Pieroni M, Sestini P, Bargagli E. Antithrombin III as predictive indicator of survival in IPF patients treated with Nintedanib: a preliminary study. Intern Med J. 2020. https:\/\/doi.org\/10.1111\/imj.14768.","DOI":"10.1111\/imj.14768"},{"issue":"5","key":"9158_CR13","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"01;198","author":"G Raghu","year":"2018","unstructured":"Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis. An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;01;198(5):e44\u201368.","journal-title":"Am J Respir Crit Care Med."},{"issue":"4","key":"9158_CR14","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1586\/17476348.2015.1062367","volume":"9","author":"I Campo","year":"2015","unstructured":"Campo I, Zorzetto M, Bonella F. Facts and promises on lung biomarkers in interstitial lung diseases. Expert Rev Respir Med. 2015;9(4):437\u201357.","journal-title":"Expert Rev Respir Med"},{"issue":"4","key":"9158_CR15","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s10238-019-00578-3","volume":"19","author":"L Bergantini","year":"2019","unstructured":"Bergantini L, Cameli P, d\u2019Alessandro M, Vagaggini C, Refini RM, Landi C, et al. NK and NKT-like cells in granulomatous and fibrotic lung diseases. Clin Exp Med. 2019;19(4):487\u201394.","journal-title":"Clin Exp Med"},{"key":"9158_CR16","doi-asserted-by":"publisher","unstructured":"d\u2019Alessandro M, Carleo A, Cameli P, Bergantini L, Perrone A, Vietri L, et al. BAL biomarkers\u2019 panel for differential diagnosis of interstitial lung diseases. Clin Exp Med [Internet]. 2020 [cited 2020 Apr 7]; Available from; 20:207\u201316. https:\/\/doi.org\/10.1007\/s10238-020-00608-5.","DOI":"10.1007\/s10238-020-00608-5"},{"issue":"1","key":"9158_CR17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s10753-013-9706-z","volume":"37","author":"E Bargagli","year":"2014","unstructured":"Bargagli E, Madioni C, Bianchi N, Refini RM, Cappelli R, Rottoli P. Serum analysis of coagulation factors in IPF and NSIP. Inflammation. 2014;37(1):10\u20136.","journal-title":"Inflammation."},{"issue":"1","key":"9158_CR18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.resinv.2016.09.003","volume":"55","author":"K Wakamatsu","year":"2017","unstructured":"Wakamatsu K, Nagata N, Kumazoe H, Oda K, Ishimoto H, Yoshimi M, et al. Prognostic value of serial serum KL-6 measurements in patients with idiopathic pulmonary fibrosis. Respir Investig. 2017;55(1):16\u201323.","journal-title":"Respir Investig"},{"key":"9158_CR19","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.cca.2013.06.002","volume":"424","author":"M Shigemura","year":"2013","unstructured":"Shigemura M, Konno S, Nasuhara Y, Shijubo N, Shimizu C, Nishimura M. Serum KL-6 concentrations are associated with molecular sizes and efflux behavior of KL-6\/MUC1 in healthy subjects. Clin Chim Acta Int J Clin Chem. 2013;424:148\u201352.","journal-title":"Clin Chim Acta Int J Clin Chem."},{"issue":"8","key":"9158_CR20","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2217\/bmm-2019-0545","volume":"14","author":"M d\u2019Alessandro","year":"2020","unstructured":"d\u2019Alessandro M, Bergantini L, Cameli P, Vietri L, Lanzarone N, Alonzi V, et al. Krebs von den Lungen-6 as a biomarker for disease severity assessment in interstitial lung disease: a comprehensive review. Biomark Med. 2020;14(8):665\u201374.","journal-title":"Biomark Med"},{"issue":"5","key":"9158_CR21","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/j.1365-2796.2006.01704.x","volume":"260","author":"H Satoh","year":"2006","unstructured":"Satoh H, Kurishima K, Ishikawa H, Ohtsuka M. Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases. J Intern Med. 2006 Nov;260(5):429\u201334.","journal-title":"J Intern Med"},{"key":"9158_CR22","volume":"20","author":"M d\u2019Alessandro","year":"2020","unstructured":"d\u2019Alessandro M, Bergantini L, Cameli P, Lanzarone N, Mazzei MA, Alonzi V, et al. Serum KL-6 levels in pulmonary Langerhans\u2019 cell Histiocytosis. Eur J Clin Investig. 2020;20:e13242.","journal-title":"Eur J Clin Investig"},{"issue":"1","key":"9158_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.resinv.2019.09.005","volume":"58","author":"L Vietri","year":"2020","unstructured":"Vietri L, Fui A, Bergantini L, d\u2019Alessandro M, Cameli P, Sestini P, et al. Serum amyloid a: a potential biomarker of lung disorders. Respir Investig. 2020 Jan;58(1):21\u20137.","journal-title":"Respir Investig"},{"issue":"1","key":"9158_CR24","doi-asserted-by":"publisher","first-page":"16571","DOI":"10.1038\/s41598-018-34901-x","volume":"8","author":"JL Ather","year":"2018","unstructured":"Ather JL, Dienz O, Boyson JE, Anathy V, Amiel E, Poynter ME. Serum amyloid A3 is required for normal lung development and survival following influenza infection. Sci Rep. 2018;8(1):16571.","journal-title":"Sci Rep"},{"issue":"5","key":"9158_CR25","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.rmed.2010.12.010","volume":"105","author":"E Bargagli","year":"2011","unstructured":"Bargagli E, Magi B, Olivieri C, Bianchi N, Landi C, Rottoli P. Analysis of serum amyloid A in sarcoidosis patients. Respir Med. 2011;105(5):775\u201380.","journal-title":"Respir Med"},{"key":"9158_CR26","doi-asserted-by":"publisher","unstructured":"Hisata S, Kimura Y, Shibata N, Ono S, Kobayashi T, Chiba S, Ohta H, Nukiwa T, Ebina M. A Normal Range of KL-6\/MUC1 Independent of Elevated SP-D Indicates a Better Prognosis in the Patients with Honeycombing on High-Resolution Computed Tomography. Pulm Med. 2011;2011:806014. https:\/\/doi.org\/10.1155\/2011\/806014.","DOI":"10.1155\/2011\/806014"},{"issue":"6","key":"9158_CR27","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1164\/rccm.201608-1675PP","volume":"15;196","author":"ML Salisbury","year":"2017","unstructured":"Salisbury ML, Myers JL, Belloli EA, Kazerooni EA, Martinez FJ, Flaherty KR. Diagnosis and treatment of fibrotic hypersensitivity pneumonia. Where we stand and where we need to go. Am J Respir Crit Care Med. 2017;15;196(6):690\u20139.","journal-title":"Am J Respir Crit Care Med."},{"issue":"3","key":"9158_CR28","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00408-019-00219-2","volume":"197","author":"MC Lopes","year":"2019","unstructured":"Lopes MC, Amadeu TP, Ribeiro-Alves M, da Costa CH, Rodrigues LS, Bessa EJC, et al. Identification of active Sarcoidosis using Chitotriosidase and angiotensin-converting enzyme. Lung. 2019;197(3):295\u2013302.","journal-title":"Lung."},{"issue":"4","key":"9158_CR29","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1080\/1744666X.2019.1568240","volume":"15","author":"M Ramos-Casals","year":"2019","unstructured":"Ramos-Casals M, Retamozo S, Sis\u00f3-Almirall A, P\u00e9rez-Alvarez R, Pallar\u00e9s L, Brito-Zer\u00f3n P. Clinically-useful serum biomarkers for diagnosis and prognosis of sarcoidosis. Expert Rev Clin Immunol. 2019;15(4):391\u2013405.","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"9158_CR30","first-page":"165","volume":"58","author":"C Landi","year":"2019","unstructured":"Landi C, Bargagli E, Carleo A, Refini RM, Bennett D, Bianchi L, et al. Bronchoalveolar lavage proteomic analysis in pulmonary fibrosis associated with systemic sclerosis: S100A6 and 14-3-3\u03b5 as potential biomarkers. Rheumatol Oxf Engl. 2019;58(1):165\u201378.","journal-title":"Rheumatol Oxf Engl"},{"key":"9158_CR31","doi-asserted-by":"crossref","unstructured":"Bergantini L, Bargagli E, Cameli P, Cekorja B, Lanzarone N, Pianigiani L, et al. Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib. Respir Investig. 2019;57(3):290\u20131.","DOI":"10.1016\/j.resinv.2019.02.001"},{"issue":"1","key":"9158_CR32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0344-0338(82)80045-9","volume":"175","author":"BH Davies","year":"1982","unstructured":"Davies BH, Williams JD, Smith MD, Jones-Williams W, Jones K. Peripheral blood lymphocytes in sarcoidosis. Pathol Res Pract. 1982;175(1):97\u2013109.","journal-title":"Pathol Res Pract"},{"key":"9158_CR33","unstructured":"Do\u011fan C. Is lymphopenia detected in sarcoidosis is associated with the disease activity? South Clin Istanb Eurasia [Internet]. 2019 [cited 2020 Apr 7]; Available from: https:\/\/www.journalagent.com\/scie\/pdfs\/SCIE_30_2_151_157.pdf"},{"key":"9158_CR34","first-page":"8(3)","volume":"28","author":"P Uysal","year":"2018","unstructured":"Uysal P, Durmus S, Sozer V, Gelisgen R, Seyhan EC, Erdenen F, et al. YKL-40, soluble IL-2 receptor, angiotensin converting enzyme and C-reactive protein: comparison of markers of sarcoidosis activity. Biomolecules. 2018;28:8(3).","journal-title":"Biomolecules"},{"issue":"5","key":"9158_CR35","doi-asserted-by":"crossref","first-page":"667","DOI":"10.5858\/134.5.667","volume":"134","author":"S Mukhopadhyay","year":"2010","unstructured":"Mukhopadhyay S, Gal AA. Granulomatous lung disease: an approach to the differential diagnosis. Arch Pathol Lab Med. 2010;134(5):667\u201390.","journal-title":"Arch Pathol Lab Med"},{"issue":"8","key":"9158_CR36","doi-asserted-by":"publisher","first-page":"4705","DOI":"10.21037\/jtd.2018.07.76","volume":"10","author":"Y Jiang","year":"2018","unstructured":"Jiang Y, Luo Q, Han Q, Huang J, Ou Y, Chen M, et al. Sequential changes of serum KL-6 predict the progression of interstitial lung disease. J Thorac Dis. 2018;10(8):4705\u201314.","journal-title":"J Thorac Dis"},{"issue":"10","key":"9158_CR37","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1164\/rccm.201505-0862OC","volume":"15;194","author":"ES White","year":"2016","unstructured":"White ES, Xia M, Murray S, Dyal R, Flaherty CM, Flaherty KR, et al. Plasma surfactant protein-D, matrix metalloproteinase-7, and osteopontin index distinguishes idiopathic pulmonary fibrosis from other idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2016;15;194(10):1242\u201351.","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"9158_CR38","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1093\/qjmed\/hcs076","volume":"105","author":"S Mahendran","year":"2012","unstructured":"Mahendran S, Sethi T. Treatments in idiopathic pulmonary fibrosis: time for a more targeted approach? QJM Mon J Assoc Physicians. 2012;105(10):929\u201334.","journal-title":"QJM Mon J Assoc Physicians"},{"key":"9158_CR39","doi-asserted-by":"publisher","first-page":"101941","DOI":"10.1016\/j.pupt.2020.101941","volume":"64","author":"C L, A C, L V, L B","year":"2020","unstructured":"C L, A C, L V, L B, d\u2019Alessandro M null PC, et al. Common molecular pathways targeted by nintedanib in cancer and IPF: a bioinformatic study. Pulm Pharmacol Ther. 2020;64:101941.","journal-title":"Pulm Pharmacol Ther"},{"key":"9158_CR40","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.cca.2020.02.022","volume":"505","author":"X-Q Huangfu","year":"2020","unstructured":"Huangfu X-Q, Wang L-G, Le Z-D, Tao B. Utility of serum amyloid A as a potential prognostic biomarker of acute primary basal ganglia hemorrhage. Clin Chim Acta Int J Clin Chem. 2020;505:43\u20138.","journal-title":"Clin Chim Acta Int J Clin Chem"},{"issue":"5","key":"9158_CR41","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.resinv.2019.03.010","volume":"57","author":"L Vietri","year":"2019","unstructured":"Vietri L, Bennett D, Cameli P, Bergantini L, Cillis G, Sestini P, et al. Serum amyloid A in patients with idiopathic pulmonary fibrosis. Respir Investig. 2019;57(5):430\u20134.","journal-title":"Respir Investig"},{"key":"9158_CR42","doi-asserted-by":"publisher","unstructured":"Kobak S, Semiz H, Akyildiz M, Gokduman A, Atabay T, Vural H. Serum adipokine levels in patients with sarcoidosis. Clin Rheumatol. 2020;39(7):2121\u20132125. https:\/\/doi.org\/10.1007\/s10067-020-04980-1.","DOI":"10.1007\/s10067-020-04980-1"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-020-09158-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-020-09158-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-020-09158-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T01:11:42Z","timestamp":1634865102000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-020-09158-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,22]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["9158"],"URL":"https:\/\/doi.org\/10.1007\/s12026-020-09158-0","relation":{},"ISSN":["0257-277X","1559-0755"],"issn-type":[{"value":"0257-277X","type":"print"},{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,22]]},"assertion":[{"value":"20 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee (Local Ethics Committee C.E. A. V. S. E. (code number 180712) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}